Biocon Biologics Insugen formulations will be available to all Ministry of Health hospitals, district health offices, and health clinics.

Biocon Biologics Limited (BBL), a subsidiary of Biocon on Tuesday said it has bagged a three-year contract valued at $90 million from the Malaysian government for the supply of recombinant human insulin brand Insugen.

Biocon Sdn Bhd., a subsidiary of Biocon Biologics, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a pharma & biotech firm in Malaysia.

Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices, and health clinics, as per an official statement.

source/content: thehindu.com (edited)